logo
logo

Zerigo Health Raises $43 Million In Series B Funding To Drive Adoption Of The Industry’S Only Connected Light Therapy Solution To Treat Chronic Skin Conditions

Oct 21, 2021•almost 4 years ago

Amount Raised

$43 Million

Round Type

series b

San DiegoHealth CareSoftware

Description

Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced a $43 million Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer. The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital. This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema

Company Information

Company

Zerigo Health

Location

San Diego, California, United States

About

Zerigo Health offers the only comprehensive home solution that seamlessly connects patients and providers to deliver optimal dermatological outcomes. Zerigo’s precision solution remotely treats and monitors patients with chronic skin conditions using narrowband ultraviolet B (NB-UVB) phototherapy, a proven, standard-of-care treatment. Patients benefit from the unique combination of advanced technology with personal coaching and support throughout their treatment journey, which results in documented increases in treatment adherence and patient satisfaction. To learn more, visit www.zerigohealth.com or on LinkedIn or Twitter.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech